Page 65 - Clinical Biochemistry

Figure 30: Hippocrates

Introduction
• Over the past few years, remarkable technological progress in the field of
pharmacogenomics (PGx) has been achieved. This field was fuelled up by the publication of
the Human Genome project in 2001.
• We all now understand that the difference between any individuals regarding their DNA
sequence is only about 0.1%. In spite of the fact that this is really a tiny figure, it is enough to
lead to important effects on disease susceptibility and progression.
• Not only this, but this little tiny percentage of difference in DNA sequence can lead to a
significant difference in the response to different therapeutic interventions.
Egyptian market needs
• Identification of the proper drugs for specific patient phenotypes will
• Heighten the drug efficacy.
• Lessen expected adverse outcomes.
• Increase cost effectiveness.
• Elevate public confidence in marketed pharmaceuticals.
• Egypt is considered a low middle income country with a population exceeding 100 million
inhabitant. There are no studies that describe the impact of ADR on the Egyptian National
Income.
• However, in Germany adverse drug reactions cause the death, hospitalization, or serious
injury of over 2 million people each year.